16 February 2018

Update on Stealth BioTherapeutics Australian Trial

Mitochondrial disease (mito) patients were given the opportunity to participate in Australia’s first pharma-led clinical trial in late 2017. Stealth BioTherapeutics’ RePOWER (SPIMM-300) study evaluated treatment of patients with Primary Mitochondrial Myopathy (PMM), by asking patients about their symptoms and quality of life.

A subsequent trial, MMPOWER-3 (SPIMM-301), which will evaluate ‘elamipretide’ as a treatment for patients with PMM, was planned to run locally. However, due to extenuating circumstances, the subsequent interventional trial will no longer take place in Australia.

The Mito Foundation has learned a lot from this process and is driven to push harder than ever to attract clinical trials to Australia, particularly by identifying and removing barriers they face. We are unrelenting in our work for the mito community and refuse to let such obstacles interfere with maximising the benefit to them.

The Mito Foundation is continually motivated by the number of clinical trials for mito underway worldwide. Click here for more information. We encourage all mito patients, those with a suspicion of mito and those with a family connection to join the Mito Patient Registry. Members will be the first to know about relevant trials. The Mito Foundation will not share members’ details with any third parties. The Registry is an invaluable tool in drawing trials to Australia. Find out more.